Monitor for follow-on activity from active managers or insider buying, as this passive inflow could precede broader institutional re-engagement. Consider that the lack of active fund participation may limit upside momentum.
Executive Summary
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased their positions in Aligos Therapeutics (ALGS) during Q4 2024, collectively purchasing $1.6 million in new shares. This represents a rare coordinated accumulation by large financial institutions in a micro-cap biotech firm, signaling renewed institutional interest despite no accompanying fundamental news in the filing.
Key Financial Metrics
Institutional Positions
Net institutional flow: $1.6M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +2312.7% | $129.0K | $128.0K |
| Wells Fargo | NEW | +0% | $869.0K | $869.0K |
| UBS | DOUBLED | +110764.3% | $618.0K | $618.0K |
Key Facts
- Morgan Stanley doubled its stake, increasing shares from 134 to 3,200 (+2,312.7%) with a value increase of $128K
- Wells Fargo established a new position of 21.8K shares, valued at $869K
- UBS increased its stake from 14 to 15,500 shares (+110,764.3%), adding $618K in value
- No institutional selling was detected in this quarter
- Total net buying amounted to $1.6 million across three mega-passive institutions
Financial Impact
Institutions accumulated $1.6M in new positions during Q4 2024
Risk Factors
- All buyers are passive index funds, suggesting the move may reflect index inclusion or rebalancing rather than fundamental conviction
- Micro-cap biotech with no recent clinical or financial updates in this filing — high volatility risk
- Low market cap ($43M) makes the stock susceptible to sharp reversals on low volume
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ALGS-2024-Q4 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | — |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | — |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | — |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | — |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | — |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | — |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | — |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers